Sfoglia per AUTORE
BANNA G
Collezione AOU San Luigi di Orbassano

  

Items : 17

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. in International immunopharmacology / Int Immunopharmacol. 2022 Sep;110:108985. doi: 10.1016/j.intimp.2022.108985. Epub 2022 Jun 28.
2022
AOU San Luigi di Orbassano

Banna GL; Cantale O; Muthuramalingam S; Cave J; Comins C; Cortellini A; Addeo A; Signori A; McKenzie H; Escriu C; Barone G; Chan S; Hicks A; Bainbridge H; Pinato DJ; Ottensmeier C; Gomes F;

International Survey on Frailty Assessment in Patients with Cancer. in The oncologist / Oncologist. 2022 Oct 1;27(10):e796-e803. doi: 10.1093/oncolo/oyac133.
2022
AOU San Luigi di Orbassano

Banna GL; Cantale O; Haydock MM; Battisti NML; Bambury K; Musolino N; O'Carroll E; Maltese G; Garetto L; Addeo A; Gomes F;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Molecular Characterization of Prostate Cancers in the Precision Medicine Era. in Cancers / Cancers (Basel). 2021 Sep 24;13(19):4771. doi: 10.3390/cancers13194771.
2021
AOU San Luigi di Orbassano

Giunta EF; Annaratone L; Bollito E; Porpiglia F; Cereda M; Banna GL; Mosca A; Marchiò C; Rescigno P;

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. in Thoracic cancer / Thorac Cancer. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1.
2021
AOU San Luigi di Orbassano

Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Porzio G; Cannita K; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Ricciardi S; Migliorino MR; Landi L; Minuti G; Tuzi A; Bordi P; Russano M; Cantini L; Santini D; Citarella F; Zoratto F; Filetti M; Mansueto G; Di Marino P; Grassadonia A; Inno A; et alii...

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). in Clinical Medicine Insights. Oncology / Clin Med Insights Oncol. 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. eCollectio
2021
AOU San Luigi di Orbassano

Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A;

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
2020
AOU San Luigi di Orbassano

Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May
2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25.
2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Baldessari C; Novello S; Bartoli G; Pizzutilo EG; Landi L; Dall'Olio FG; Toschi L; Sartori G; Ciccone LP; Garassino MC; Guaitoli G; Zanelli F; De Carlo E; Bearz A; Camerini A; Sala E; Migliorino MR; Cerea G; Ardizzoni A; Bennati C; Vita E; Del Conte A; Rossi S; Scotti V; Pilotto S; Cecere FL; Proto C; Berardi R; Mazzoni F; et alii...

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. in Current oncology reports / Curr Oncol Rep. 2019 Nov 25;21(12):107. doi: 10.1007/s11912-019-0852-9.
2019
AOU San Luigi di Orbassano

Friedlaender A; Banna GL; Buffoni L; Addeo A;

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. in PloS one / PLoS One. 2019 Nov 13;14(11):e0224027. doi: 10.1371/journal.pone.0224027. eCollection 2019.
2019
AOU San Luigi di Orbassano

Bruni A; Giaj-Levra N; Ciammella P; Maragna V; Ferrari K; Bonti V; Grossi F; Greco S; Greco C; Borghetti P; Franceschini D; Capelletto E; Perna M; Banna G; Vagge S; Baldini E; Bria E; Botti A; Tiseo M; Paci M; Taraborrelli M; Poletti V; Granone P; Ricardi U; Novello S; Scotti V;

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26.
2016
AOU San Luigi di Orbassano

Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S;

Maintenance therapy in NSCLC: why? To whom? Which agent? in Journal of experimental & clinical cancer research : CR / J Exp Clin Cancer Res. 2011 May 6;30(1):50. doi: 10.1186/1756-9966-30-50.
2011
AOU San Luigi di Orbassano

Novello S; Milella M; Tiseo M; Banna G; Cortinovis D; Di Maio M; Garassino M; Maione P; Martelli O; Vavalà T; Bria E;